denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Bleeding and Clotting, Clinical Practice (Health Services and Quality), Diseases, Treatment Considerations
Description:
Patients with cancer have an increased risk of venous thromboembolism (VTE) for which anticoagulation is the treatment of choice. However, they also commonly face complications related to cancer itself or cancer therapies that create unique challenges for the management of cancer-associated thrombosis. This educational session will explore the evidence for best practices in assessing and managing challenging scenarios in patients with cancer-associated thrombosis, including patients with brain metastasis, recurrent venous thromboembolism despite anticoagulation, and thrombocytopenia.
Dr. Leader will summarize the evidence of anticoagulant use in patients with brain metastasis, discuss risks and benefits of anticoagulation in these patients and optimal management strategies in this high-risk population.
Dr. Zwicker will discuss the challenges of evaluating and managing patients with cancer and new or progressive VTE on anticoagulation. He will discuss diagnostic strategies to identify etiologies for anticoagulant failure and provide therapeutic options in this patient population.
Dr. Ay will address the challenge of concurrent VTE and thrombocytopenia in patients with cancer. He will summarize data from available literature, review guidance recommendations, and discuss management strategies and future directions in these patients.
Dr. Leader will summarize the evidence of anticoagulant use in patients with brain metastasis, discuss risks and benefits of anticoagulation in these patients and optimal management strategies in this high-risk population.
Dr. Zwicker will discuss the challenges of evaluating and managing patients with cancer and new or progressive VTE on anticoagulation. He will discuss diagnostic strategies to identify etiologies for anticoagulant failure and provide therapeutic options in this patient population.
Dr. Ay will address the challenge of concurrent VTE and thrombocytopenia in patients with cancer. He will summarize data from available literature, review guidance recommendations, and discuss management strategies and future directions in these patients.